Heidi Crayton, MD, and Maria Lopes, MD, discuss the impact of multiple sclerosis on patients, families, and caregivers, differentiate relapsing forms (relapsing-remitting and primary progressive) from ...

"Seventeen of the patients in our study had brain pathology available, all of whom had findings typical of multiple sclerosis. Immunopathological phenotyping was performed in 13 patients, all of whom ...

Multiple sclerosis (MS) is a central nervous system immune-mediated inflammatory demyelinating disease. A relapsing-remitting course, a progressive disease course, or a combination of the two may ...

Researchers demonstrate the relationship between the rate of cognitive fatigue in MS and microstructural brain changes. The findings promise to advance development of clinical interventions for ...

Immunological memory - the ability to respond to a previously encountered antigen, or foreign substance, with greater speed and intensity on re-exposure is a hallmark of adaptive immunity. Innate ...

Systematic analyses of the complex interplay of genetic and environmental factors that regulate immune cells are key in unraveling the pathophysiology of multiple sclerosis (MS). However, the ...

Amyloid pathology typical of Alzheimer's disease (AD) is 50% lower in patients with multiple sclerosis (MS) than in those without the condition, an analysis of plasma biomarker data shows.

Sanofi provides update on tolebrutinib in primary progressive multiple sclerosisPERSEUS phase 3 study in primary progressive multiple sclerosis ...

# Studying the impact of personality traits in Multiple Sclerosis.

Clinicians and health system leaders met in Portland, Oregon, on October 21, 2025, to discuss the evolving options for treating Alzheimer disease and multiple sclerosis.